Dying mammalian cells emit numerous signals that interact with the host to dictate the
immunological correlates of cellular stress and death. In the absence of reactive antigenic …

Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …

With emerging supremacy, cancer immunotherapy has evolved as a promising therapeutic
modality compared to conventional antitumor therapies. Cancer immunotherapy composed …

Abstract Toll-like receptors (TLRs), which serve as a bridge between innate and adaptive
immunity, may be viable treatment targets. TLRs are the first line of defense against …

Most metastatic cancers remain incurable due to the emergence of apoptosis-resistant
clones, fuelled by intratumour heterogeneity and tumour evolution. To improve treatment …

Colorectal cancer (CRC) is one of the most common cancers worldwide. Current therapies
such as surgery, chemotherapy, and radiotherapy encounter obstacles in preventing …

Glioma represents a fast proliferating and highly invasive brain tumor which is resistant to
current therapies and invariably recurs. Despite some advancements in anti-glioma …

Stimulator of interferon genes (STING) is an important adaptor in cytosolic DNA-sensing
pathways. A recent study found that the deletion of STING ameliorated cisplatin-induced …

Immune checkpoint therapies (ICT) can reinvigorate the effector functions of anti-tumour T
cells, improving cancer patient outcomes. Anti-tumour T cells are initially formed during their …

Accumulating evidence indicates that Toll-like receptor (TLR) agonists proficiently (re)
instore cancer immunosurveillance as immunological adjuvants. So far, three TLR agonists …